Related references
Note: Only part of the references are listed.Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy
Alberto B. Burlina et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017
Dana Doheny et al.
JOURNAL OF MEDICAL GENETICS (2018)
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
Elfrida R. Benjamin et al.
GENETICS IN MEDICINE (2017)
The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies
Peter D. Stenson et al.
HUMAN GENETICS (2017)
X-chromosome inactivation in female patients with Fabry disease
L. Echevarria et al.
CLINICAL GENETICS (2016)
Is it Fabry disease?
Raphael Schiffmann et al.
GENETICS IN MEDICINE (2016)
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat
D. P. Germain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
Dominique P. Germain et al.
JOURNAL OF MEDICAL GENETICS (2015)
A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects
R. Giugliani et al.
MOLECULAR GENETICS AND METABOLISM (2013)
Fabry Disease: Incidence of the Common Later-Onset α-Galactosidase A IVS4+919G→A Mutation in Taiwanese Newborns-Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations
Yin-Hsiu Chien et al.
MOLECULAR MEDICINE (2012)
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
Dominique P. Germain et al.
ORPHANET JOURNAL OF RARE DISEASES (2012)
A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease
Xiaoyang Wu et al.
HUMAN MUTATION (2011)
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Raphael Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy
Lorenzo Monserrat et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
High incidence of later-onset Fabry disease revealed by newborn screening
Marco Spada et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a renal variant phenotype
S Nakao et al.
KIDNEY INTERNATIONAL (2003)
Fabry disease:: Novel α-galactosidase A 3′-terminal mutations result in multiple transcripts due to aberrant 3′-end formation
M Yasuda et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
